603579 Shanghai Rongtai Health Technology Corporation
- 24.10
- -0.20-0.82%
Shanghai Rongtai Health Technology Corporation News
Rongtai Convertible Bonds: The conversion price will be adjusted from 31.66 yuan/share to 23.78 yuan/share
Shanghai Rongtai Health Technology Co., Ltd. announced that due to the 2023 profit distribution, the “Rongtai Bonds” conversion price will be adjusted from 31.66 yuan/share to 23.78 yuan/share, effective from June 5, 2024. The company has suspended share swaps and will resume on June 5.
Rongtai Health (603579.SH) plans to distribute 10 yuan to 3 shares for every 10 shares in 2023, excluding interest on June 5
Rongtai Health (603579.SH) announced that in 2023, the company plans to distribute cash to all shareholders for every 10 shares...
Rongtai Health (603579): Remarkable results in cost reduction and efficiency, impressive performance growth
Incident description The company disclosed a quarterly report: The company achieved operating income of 401 million yuan in Q1 of 2024, an increase of 3.86% over the previous year, and achieved net profit of 63 million yuan, an increase of 67.31% over the previous year, and achieved net deduction without return to mother
Rongtai Health: No downward revisions to the “Rongtai Bonds” conversion price
Shanghai Rongtai Health Technology Co., Ltd. announced that as of May 16, 2024, the company's stock price had experienced a situation where the closing price for at least 15 out of 30 consecutive trading days was less than 80% of the current share conversion price, triggering a downward revision of the “Rongtai Bonds” conversion price. After deliberation and approval at the 16th meeting of the fourth board of directors held on May 16, 2024, the board of directors of the company decided not to revise the “Rongtai Bonds” conversion price downward this time, and within the next six months (that is, from May 17, 2024 to November 16, 2024), if the “Rongtai Bonds Transfer” share conversion price is triggered again
Rongtai Health: “Rongtai Bonds Transfer” is expected to trigger downward correction conditions for share conversion prices
Shanghai Rongtai Health Technology Co., Ltd. announced that from April 23, 2024 to May 9, 2024, the closing price of the company's stock was lower than 80% of the current conversion price (25.33 yuan/share) for 10 trading days, which is expected to trigger downward revision conditions for the share conversion price.
Rongtai Health (603579): Profitability significantly improved in 2024Q1, regional structure optimization
Event: On April 25, 2024, Rongtai Health released its 2024 quarterly report. 2024Q1 revenue/net profit attributable to mother/net profit excluding non-return to mother were 4.01/0.61 billion yuan, respectively, year-on-year share
Rongtai Health (603579): Export revenue was slightly pressured, profit improved sharply, exceeding expectations
Report guide: Rongtai Health released its 2024 quarterly report. The company achieved revenue of 401 million yuan in 24Q1, +3.86% year over year; net profit to mother of 62.74 million yuan, +67.31% year over year; net profit after deduction 6
Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflect
Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflection point in Q4; 2) falling raw material prices & optimization of product and customer structures, and improvement in profit levels. (Mainichi Keizai Shimbun)
Rongtai Health (603579) Company Brief Review Report: Q4 Revenue Growth Inflection Point Upward, Profitability Continues to Repair
Incident: The company released its 2023 annual report, achieving full-year revenue of 1,855 million yuan, -7.47%; net profit to mother of 203 million yuan, +23.43% year-on-year; net profit after deducting non-return to mother of 186 million, +47 year-on-year
Rongtai Health (603579): Structural optimization, cost reduction, efficiency, continuous improvement of operating efficiency
Incident description The company disclosed the annual report and performance forecast: in 2023, the company achieved operating income of 1,855 billion yuan, a year-on-year decrease of 7.47%, net profit to mother 203 million yuan, an increase of 23.43% year-on-year, and deducted non-net profit from the mother
Dongfang Wealth Securities released a research report on April 18 stating that it gave Rongtai Health (603579.SH) an increase in its holdings. The main reasons for the rating include: 1) the company's release of the 2023 annual report and the performance
Dongfang Wealth Securities released a research report on April 18 stating that it gave Rongtai Health (603579.SH) an increase in its holdings. The main reasons for the rating include: 1) the company's release of the 2023 annual report and the performance forecast for the first quarter of 2024; 2) weak global consumer demand and pressure on the revenue side; 3) supply chain optimization, product restructuring, and profitability improvement; 4) increase in dividend rates to give back to shareholders. (Mainichi Keizai Shimbun)
Rongtai Health (603579.SH): It already has certain technical reserves in car massage chairs
Gelonghui, April 18 | Rongtai Health (603579.SH) said on the investor interactive platform that the company already has certain technical reserves for car massage chairs.
Southwest Securities released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a holding rating. The main reasons for the rating include: 1) weak domestic market demand and pressure on orders in the Korean and US markets; 2) s
Southwest Securities released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a holding rating. The main reasons for the rating include: 1) weak domestic market demand and pressure on orders in the Korean and US markets; 2) significant increase in gross margin of export sales, driving improved profitability; 3) demand for massage chairs is under pressure, and the company actively adjusts overseas teams. (Mainichi Keizai Shimbun)
Rongtai Health (603579): 2024Q1 performance exceeds expectations and high dividends boost shareholders' confidence
Event: On April 15, 2024, Rongtai Health released the 2023 Annual Report and the first quarter results forecast for 2024. In 2023, the company achieved revenue of 1,855 billion yuan (-7.47%); net profit to mother
Pacific released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) rapid revenue growth in 2023Q4 and domestic and foreign two-wheel drive sales growth; 2) 2023Q4 p
Pacific released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) rapid revenue growth in 2023Q4 and domestic and foreign two-wheel drive sales growth; 2) 2023Q4 profitability improvement, reflecting the advantages of cost reduction and efficiency; 3) 2023 high dividend returns to shareholders, and high dividend rates highlight value; 4) continuous innovation in technology research and development, and channel changes drive performance growth. (Mainichi Keizai Shimbun)
Shares with pre-performance gains have strengthened, and the same shares have 4 consecutive shares
Gelonghui, April 17 | The same shares have 4 consecutive shares, 2 consecutive shares of Rongtai Health. Lishang Guochao, Haomei New Materials, and Kehua Holdings bid up and down, and Zhaomin Technology and Baiwei Storage are over 10% higher. According to the news, Lishang Guochao expects net profit for the first quarter to increase 145%-161% year on year; Baiwei Storage expects to turn a loss of 150 million yuan to 180 million yuan in the first quarter; Zhaomin Technology expects net profit to increase 68%-97% year on year in the first quarter; Haomei New Materials achieved a 178% year-on-year increase in net profit in the first quarter; and Kehua Holdings' net profit increase 531% year on year in 2023.
Rongtai Health (603579): Domestic and foreign sales adjustments have passed the bottom, and management improvements can be expected
The investment recommended that we raise Rongtai Health's rating from neutral to outperforming the industry. The reasons are as follows: Export: End of inventory removal cycle, restructuring of major Korean customers. 1) The company's export revenue 2022/2023 YoY -19.2% /-8.
Rongtai Health (603579): High dividend Q1 performance exceeded expectations
Event Overview The company released its 2023 annual report and pre-increase results announcement for the first quarter of '24:23: total operating revenue of 1,855 billion yuan (YOY -7.47%), net profit to mother of 203 million yuan (YOY+23)
Rongtai Health (603579): Export business continues to recover, Q4 revenue growth rate corrected
Event: Rongtai Health announced its 2023 annual report and pre-increase results for the first quarter of 2024. In 2023, it achieved revenue of 1.86 billion yuan, YoY -7.5%, realized net profit of 200 million yuan to mother, YoY+23
A-share high-performing growth stocks are sought after, Ganneng shares, and Rongtai Health rose and stopped
Gelonghui, April 16 | It is also a three-time stock market. Ganneng shares and Rongtai Health rose and stopped. Haixing Electric Power came close to rising or stopping, and Jinaobo and Gaibao Pet rose more than 5%.
Analysis
Price Target
No Data
